Abstracts tagged "Disease Activity"

Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Marije K Verheul², Anne Barton^3,4, Tarnya Marshall⁵, Bo Fu⁶, René E.M. Toes⁷, Deborah PM Symmons^1,4, Leendert A. Trouw⁷ and Suzanne MM Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁶Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia. However, little is known about their association with disease…
Abstract Number: 1631 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Richard Furie¹, Jill P. Buyon², R. Ramsey-Goldman³, Chaim Putterman⁴, Kenneth Kalunian⁵, Tyler O'Malley⁶, John Conklin⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: To assess the association between cell bound complement activation products (CBCAPS) and measures of disease activity and quality of life in systemic lupus erythematosus…
Abstract Number: 1352 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists
Anne Winkler¹, James Mossell², Edmund MacLaughlin³, Drew Johnson⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Winkler Medical Practice LLC, Springfield, MO, ²Arthritis & Osteo Center of South GA, Tifton, GA, ³Edmund L. MacLaughlin LLC, Cambridge, MD, ⁴Crescendo Bioscience, Inc., South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Timely disease activity assessment (DAA) and population management (PM) are known to reduce the burdens of chronic diseases, including RA. Currently, the measures and…
Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Sara K. Tedeschi¹, Hongshu Guan¹, Alexander Fine¹, Bonnie L. Bermas² and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…
Abstract Number: 570 • 2014 ACR/ARHP Annual Meeting
Sleep Disturbances in Korean Patients with Ankylosing Spondylitis Are Associated with Increased Disease Activity
Hye-Jin Jeong¹, Yun Sung Kim², Chang-Nam Son³, Ji-Min Kim³ and Sang-Hyon Kim³, ¹Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Sleep problems have been reported to be more frequent in rheumatic disease than normal population. Other studies indicate various sleep problems have been reported…
Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting
Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Beverley Almeida¹, Raquel Campanilho-Marques², Katie Arnold², Lucy R. Wedderburn^3,4, Clarissa A Pilkington⁵ and Kiran Nistala⁶, ¹Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁵Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
Abstract Number: 2568 • 2014 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort
Isabel Castrejón¹, Theodore Pincus¹, Daniel Wendling² and Maxime Dougados³, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France, ³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose The Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) –an index of only patient-self-report measures - has been the most widely used measure in…
Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Ruediger Mueller¹, Johannes von Kempis¹, Michael H Schiff² and Sarah Haile³, ¹Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland, ²University of Colorado, Denver, CO, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…
Abstract Number: 1608 • 2014 ACR/ARHP Annual Meeting
Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis
Jill P. Buyon¹, R. Ramsey-Goldman², Richard Furie³, Chaim Putterman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁷Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Biomarkers of renal response in patients with systemic lupus erythematosus (SLE) may provide clues to pathogenesis and drive translation to treatment. This study was…
Abstract Number: 1324 • 2014 ACR/ARHP Annual Meeting
Predictors of Disease Relapse in Juvenile Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski² and Christina Kelsey³, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA
Background/Purpose Localized scleroderma (LS) is an autoimmune disease characterized by inflammation of the skin and underlying tissue leading tissue damage including atrophy, dyspigmentation, and fibrosis. …
Abstract Number: 866 • 2014 ACR/ARHP Annual Meeting
Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe⁴, David Albert⁵, Judith A. James⁶ and Joan T. Merrill³, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵AliveCor, Inc., San Francisco, CA, ⁶Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heart rate variability (HRV) is a marker of vagus nerve activity and can be easily obtained with minimal technical expertise in the outpatient setting,…
Abstract Number: 556 • 2014 ACR/ARHP Annual Meeting
Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling³, ¹Rheumatology, CHRU, Besançon, France, ²Investigation Center, CHRU, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: Spondyloarthritis (SpA) activity varies with time and treatment, but to date no clear definition of a flare of the disease is available. The aim…
Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Ronald F. van Vollenhoven¹, Rebecca J. Bolce², Karen Hambardzumyan³, Saedis Saevarsdottir⁴, Kristina Forslind⁴, Ingemar Petersson⁵, Eric H. Sasso², CC Hwang⁶, Oscar Segurado² and Pierre Geborek⁷, ¹Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³ClinTRID, the Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ⁶Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].